ATE230607T1 - Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust - Google Patents

Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust

Info

Publication number
ATE230607T1
ATE230607T1 AT98937956T AT98937956T ATE230607T1 AT E230607 T1 ATE230607 T1 AT E230607T1 AT 98937956 T AT98937956 T AT 98937956T AT 98937956 T AT98937956 T AT 98937956T AT E230607 T1 ATE230607 T1 AT E230607T1
Authority
AT
Austria
Prior art keywords
hearing loss
prevent
neurturin protein
treat hearing
methods
Prior art date
Application number
AT98937956T
Other languages
English (en)
Inventor
Ella Magal
John M Delaney
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE230607T1 publication Critical patent/ATE230607T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98937956T 1997-07-30 1998-07-17 Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust ATE230607T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5418497P 1997-07-30 1997-07-30
US09/106,486 US6043221A (en) 1997-07-30 1998-06-29 Method for preventing and treating hearing loss using a neuturin protein product
PCT/US1998/014600 WO1999006064A1 (en) 1997-07-30 1998-07-17 Method for preventing and treating hearing loss using a neurturin protein product

Publications (1)

Publication Number Publication Date
ATE230607T1 true ATE230607T1 (de) 2003-01-15

Family

ID=26732740

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937956T ATE230607T1 (de) 1997-07-30 1998-07-17 Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust

Country Status (10)

Country Link
US (2) US6043221A (de)
EP (1) EP1005358B1 (de)
JP (1) JP2001525316A (de)
AT (1) ATE230607T1 (de)
AU (1) AU8658298A (de)
CA (1) CA2298414C (de)
DE (1) DE69810635T2 (de)
DK (1) DK1005358T3 (de)
ES (1) ES2190093T3 (de)
WO (1) WO1999006064A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
JP2003530817A (ja) 1999-06-01 2003-10-21 ベイラー カレッジ オブ メディスン 聴覚障害、変形性関節症および細胞の異常増殖に関するａｔｏｎａｌ関連配列の治療用途のための組成物および方法
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
AU2003208900A1 (en) * 2002-01-30 2003-09-02 House Ear Institute L-carnitine for treatment of hearing loss
EP2275118A3 (de) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Pankreas spezifische proteine
CN100335502C (zh) * 2002-06-27 2007-09-05 学校法人日本医科大学 外淋巴瘘的检测方法
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
DE60332748D1 (de) 2002-10-02 2010-07-08 Anges Mg Inc Arzneimittel gegen hörfunktionsstörungen
WO2004066975A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
DE602004021847D1 (de) 2003-11-27 2009-08-13 Develogen Ag Verfahren zur prävention und behandlung von diabetes mit neurturin
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
KR20070027621A (ko) * 2004-06-08 2007-03-09 알자 코포레이션 4-성분 축합 반응에 의한 고분자 콘쥬게이트의 제조
CA2569724A1 (en) 2004-06-15 2005-12-29 Cochlear Americas Automatic determination of the threshold of an evoked neural response
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US9265933B2 (en) 2005-09-08 2016-02-23 Massachusetts Eye And Ear Infirmary Cochlear implants containing biological cells and uses thereof
EP1872790A1 (de) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft Neue Zusammensetzung zur Erhöhung der Bioverfügbarkeit von Neurturin
WO2009059755A2 (en) * 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2278999B1 (de) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
CN102695723A (zh) * 2009-10-30 2012-09-26 中枢神经系统治疗学公司 改进的神经营养因子分子
US20110195488A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Devices for collection and stabilization of biomarkers in liquid samples
ES2906726T3 (es) * 2014-06-12 2022-04-20 Adare Pharmaceuticals Usa Inc Composiciones de administración de fármaco de liberación prolongada
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
WO2020045980A1 (en) * 2018-08-28 2020-03-05 Industry-Academic Cooperation Foundation, Yonsei University Pharmaceutical composition for treating or preventing sensorineural hearing loss
CN110124014A (zh) * 2019-05-16 2019-08-16 杭州师范大学 重组人神经突起生长因子Neuritin蛋白的应用及一种用于治疗听神经病的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
AU1121997A (en) * 1995-11-29 1997-06-19 Amgen, Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product

Also Published As

Publication number Publication date
ES2190093T3 (es) 2003-07-16
DE69810635D1 (de) 2003-02-13
AU8658298A (en) 1999-02-22
DK1005358T3 (da) 2003-02-24
WO1999006064A1 (en) 1999-02-11
CA2298414A1 (en) 1999-02-11
CA2298414C (en) 2004-09-28
US6043221A (en) 2000-03-28
DE69810635T2 (de) 2003-05-28
EP1005358A1 (de) 2000-06-07
US6274554B1 (en) 2001-08-14
JP2001525316A (ja) 2001-12-11
EP1005358B1 (de) 2003-01-08

Similar Documents

Publication Publication Date Title
ATE230607T1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE211392T1 (de) Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69527052D1 (de) Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE60040860D1 (de) Mechanisch verlängerte neuronale zellen und methoden zur herstellung und verwendung dieser zellen
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
EP1304119A3 (de) Verfahren zur Vorbeugung und Behandlung von Gehörverlust mit Neurturin Protein
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
NZ323207A (en) Hemoregulatory compounds
WO2000061180A3 (en) Products and methods for treating ptp lar related diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1005358

Country of ref document: EP

REN Ceased due to non-payment of the annual fee